- Home
- ICCM vs SKYE Comparison
ICCM vs SKYE Comparison
Compare ICCM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- SKYE
- Stock Information
- Founded
- ICCM 2006
- SKYE 2012
- Country
- ICCM Israel
- SKYE United States
- Employees
- ICCM N/A
- SKYE N/A
- Industry
- ICCM
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- SKYE Health Care
- Exchange
- ICCM Nasdaq
- SKYE Nasdaq
- Market Cap
- ICCM 70.1M
- SKYE 80.7M
- IPO Year
- ICCM N/A
- SKYE N/A
- Fundamental
- Price
- ICCM $1.03
- SKYE $1.79
- Analyst Decision
- ICCM Strong Buy
- SKYE Buy
- Analyst Count
- ICCM 1
- SKYE 6
- Target Price
- ICCM $2.50
- SKYE $16.60
- AVG Volume (30 Days)
- ICCM 196.6K
- SKYE 1.7M
- Earning Date
- ICCM 05-27-2025
- SKYE 05-08-2025
- Dividend Yield
- ICCM N/A
- SKYE N/A
- EPS Growth
- ICCM N/A
- SKYE N/A
- EPS
- ICCM N/A
- SKYE N/A
- Revenue
- ICCM $3,291,000.00
- SKYE N/A
- Revenue This Year
- ICCM $97.02
- SKYE N/A
- Revenue Next Year
- ICCM $212.86
- SKYE N/A
- P/E Ratio
- ICCM N/A
- SKYE N/A
- Revenue Growth
- ICCM 1.92
- SKYE N/A
- 52 Week Low
- ICCM $0.48
- SKYE $1.14
- 52 Week High
- ICCM $1.66
- SKYE $13.49
- Technical
- Relative Strength Index (RSI)
- ICCM 37.29
- SKYE 47.86
- Support Level
- ICCM $1.00
- SKYE $1.36
- Resistance Level
- ICCM $1.34
- SKYE $2.30
- Average True Range (ATR)
- ICCM 0.08
- SKYE 0.20
- MACD
- ICCM -0.01
- SKYE 0.03
- Stochastic Oscillator
- ICCM 8.82
- SKYE 45.74
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.